SecBot SecBot
SECBOTREPLAY Home › Report › AZTR

AZTR · Azitra issued a press release announcing a presentation at BIO-Europe…

Azitra, Inc. · PRESS-RELEASE filed Nov 10, 2026 at 08:30 ET

At the news

NEUTRALIMPACT 3/10

PRESS-RELEASE filed Nov 10, 2026 at 08:30 ET

Azitra issued a press release announcing a presentation at BIO-Europe 2026 highlighting initial ex vivo data for ATR-COSF, a recombinant filaggrin protein for cosmetic use, showing a 56% reduction in wrinkles from baseline. The company also provided an update on its Phase 1/2 trial of ATR-04, which was expanded to include patients with rashes from KRAS and MEK inhibitors. No financial results or guidance were provided.

  • ATR-COSF showed a 56% reduction in wrinkles from baseline in an ex vivo human torso skin model.
  • ATR-COSF improved elasticity and wrinkle depth compared to vehicle in ex vivo models at 48 hours.
  • Phase 1/2 trial of ATR-04 expanded in October 2026 to include patients with rashes due to KRAS and MEK inhibitors, and NF1 patients with rash from MEK inhibitors.
  • Approximately 85,000 patients undergo KRAS or MEK inhibitor treatment annually in the U.S., in addition to ~220,000 on EGFR inhibitors.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access